From August 25 to 27, 2026, CPHI Korea 2026, the renowned Asian pharmaceutical industry event, was grandly held at COEX Convention & Exhibition Center in Seoul. As one of the key commercial platforms for connecting East‑Asian markets, the exhibition gathered pharmaceutical enterprises, API suppliers and industry procurement decision‑makers from across the globe to explore new opportunities for the development of the pharmaceutical industry. Sichuan Xieli Pharmaceutical Co., Ltd. took part in the exhibition in South Korea once again. Following our exhibition theme of “Plant‑Derived Technology, Shared Globally”, the company showcased its strengths and international achievements in natural‑source specialty APIs at Booth J24.

Exhibition Site | Star Products on Display, Multiple International Certificates Demonstrate Quality

At this exhibition, Xieli Pharma highlighted a range of competitive specialty APIs and plant‑extracted products, including core varieties such as Ursodeoxycholic acid, Diosmin, Hesperidin, Rutin, Troxerutin and Berberine hydrochloride. It featured its core product portfolio of flavonoids and cholic‑acid series, and also presented its CDMO custom manufacturing capabilities.

Multiple international certifying including EU CEP, US FDA inspection compliance and other GMP certificates were displayed at the booth, fully demonstrating the rigorous quality control system of Xieli. During the exhibition, a steady stream of visitors came for inquiries at our Booth J24. Pharmaceutical purchasers and technical experts from South Korea, Southeast Asia, Europe, America and other regions stopped for in‑depth exchanges covering product processes, impurity control, production capacity supply, regulatory compliance and custom development. Positive business discussions took place on‑site.

In‑depth Exchanges | Connecting to East‑Asian Market, Building Consensus for Cooperation

Over the three‑day exhibition, the international trade and domestic sales teams of Xieli Pharma engaged with customers at home and abroad. On one hand, the team paid return visits to long‑term stable customers, reviewing supply‑chain assurance and product iteration and upgrading. On the other hand, the team actively engaged potential new partners in East Asia, exchanging views on regulatory requirements of South‑Korean and Asia‑Pacific markets as well as demands from downstream pharmaceutical preparation and health‑product markets, and reached multiple preliminary cooperation intentions regarding long‑term stable supply and joint new‑product development.

Through the platform of CPHI Korea, the team conducted on‑site research on the latest trends of the Asia‑Pacific pharmaceutical market and collected cutting‑edge industry demands, accumulating valuable first‑hand market information for subsequent product layout, process optimisation and market expansion.

Looking Ahead | Upholding Quality, Further Exploring Global Markets

Global market demand for natural‑source APIs keeps growing. Rooted in core technologies for plant extraction, Xieli Pharma consistently takes quality as the foundation, keeps advancing its international product layout, and continuously improves the full chain R&D — Manufacturing — Supplying system. We are committed to providing stable and compliant API supply services for global partners.

This participation in the Seoul exhibition constitutes an important part of Xieli Pharma’s Asia‑Pacific market layout. Going forward, relying on the global CPHI exhibition series, Xieli will further strengthen links with the pharmaceutical sector in East Asia and worldwide, deliver high‑quality plant derived APIs, and work with global pharmaceutical peers to promote high‑quality development of the broader health industry.